STOCK TITAN

Cue Biopharma, Inc. - $CUE STOCK NEWS

Welcome to our dedicated page for Cue Biopharma news (Ticker: $CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.

Cue Biopharma, Inc. (Nasdaq: CUE) is a pioneering clinical-stage biopharmaceutical company located in Boston, Massachusetts. The company focuses on developing a novel class of injectable biologics designed to selectively engage and modulate disease-specific T cells directly within the patient's body. Cue Biopharma’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), aims to harness the body’s intrinsic immune system as T cell engagers, minimizing the need for ex vivo manipulation and broad systemic immune modulation.

The company's leading clinical programs include CUE-101 and CUE-102. CUE-101 is being evaluated for the treatment of recurrent/metastatic HPV16+ head and neck squamous cell carcinoma both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). Recent data from Phase 1 trials have shown promising results, including prolonged overall survival and enhanced clinical activity when combined with pembrolizumab.

CUE-102 targets Wilms' Tumor 1 (WT1)-expressing cancers such as colorectal, gastric, and pancreatic cancers. Early Phase 1 trial data for CUE-102 has demonstrated expansion of WT1-specific T cells and favorable tolerability, pointing to potential therapeutic benefits for cancers resistant to traditional treatments.

Additionally, Cue Biopharma is advancing its preclinical program CUE-401 for autoimmune and inflammatory diseases in collaboration with Ono Pharmaceutical. This program aims to redirect virus-specific T cells to deplete B cells in autoimmune conditions.

Financially, Cue Biopharma reported increased collaboration revenue due to its strategic agreement with Ono Pharmaceutical. Despite higher research and development expenses, the company maintains a strong cash position, with approximately $41 million in cash and equivalents expected to fund operations into the first quarter of 2025. The management team, led by CEO Daniel Passeri, continues to focus on strategic corporate objectives, including potential registrational trials for CUE-101 and advancing other therapeutic candidates.

With an experienced leadership and independent Board of Directors, Cue Biopharma is well-positioned to make significant strides in the fields of oncology and autoimmune disease treatment, aiming to deliver transformative therapies for patients while creating value for its shareholders.

Rhea-AI Summary

Cue Biopharma has presented updated data from its Phase 1 trial of CUE-101 at the 2024 ASCO Annual Meeting, revealing promising results for HPV+ head and neck cancer. The combination of CUE-101 and pembrolizumab in first-line (1L) treatment showed a 46% overall response rate (ORR) and a 96% 12-month overall survival (OS). For second-line (2L) and beyond, median overall survival (mOS) was 20.8 months with CUE-101 monotherapy, significantly higher than historical comparisons. No significant safety concerns emerged. Additionally, early data from CUE-102 indicated positive immune response and tolerability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
-
Rhea-AI Summary

Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in two significant investor healthcare conferences this June 2024. The company, listed on Nasdaq with the ticker CUE, focuses on developing therapeutic biologics targeting disease-specific T cells.

On June 6, Cue Biopharma will present at the Jefferies Global Healthcare Conference in New York, discussing its progress in oncology and autoimmune platforms. The presentation by Anish Suri, Ph.D., President and Chief Scientific Officer, will be available via webcast.

On June 24, the company will participate in the Oppenheimer Novel Targets and Immunology Summit, also in New York. Dr. Suri will join a panel to discuss repurposing cancer targets for immunology. These events will provide updates on clinical and preclinical advancements and strategic approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences
-
Rhea-AI Summary

Cue Biopharma, Inc. reported their first-quarter 2024 financial results, showcasing an increase in collaboration revenue to $1.7 million due to partnerships. They highlighted advancements in clinical trials for CUE-101 and CUE-102, as well as the expansion of their pipeline to include programs for autoimmune and inflammatory diseases. The company emphasized progress in their autoimmune program, CUE-401, with Ono Pharmaceutical, and the development of the bispecific Immuno-STAT CUE-500 series. Financially, Cue Biopharma reported $41.0 million in cash and cash equivalents as of March 31, 2024, with expectations to fund operations into the first quarter of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.14%
Tags
Rhea-AI Summary

Cue Biopharma, Inc. (Nasdaq: CUE) is set to present at the 20th PEGS Boston Summit with two poster presentations discussing their innovative Immuno-STAT biologics for targeting autoimmune diseases and immuno-oncology. The presentations will cover the CUE-500 series for depleting B cells in autoimmune diseases and the Immuno-STAT platform for cancer and inflammatory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.39%
Tags
conferences
-
Rhea-AI Summary

Cue Biopharma, Inc. (Nasdaq: CUE) will participate in a fireside chat at The Citizens JMP Life Sciences Conference in New York to discuss current oncology and autoimmune disease strategies and progress. The webcast of the chat will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
conferences
-
Rhea-AI Summary
Cue Biopharma, Inc. (Nasdaq: CUE) will present at the 2024 American Society of Clinical Oncology Annual Meeting. The company will showcase Phase 1 trials of CUE-101 and CUE-102 in head and neck cancer and recurrent/metastatic cancers. There will be an oral abstract and poster presentation, with a Business Update call and webcast scheduled for June 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
conferences
Rhea-AI Summary
Cue Biopharma, Inc. reported positive data from Phase 1 trials of CUE-101 and CUE-102 for cancer treatment. The company completed enrollment for CUE-101 trials and received FDA guidance for potential registrational trials. Financially, collaboration revenue increased significantly in 2023, with research and development expenses slightly decreasing. However, the company's cash reserves declined, with operations expected to be funded until Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.86%
Tags
-
Rhea-AI Summary
Cue Biopharma, Inc. (CUE) will host a conference call and webcast to provide a business update on April 8, 2024. The update will focus on advancing its clinical oncology programs, CUE-101 and CUE-102, as well as its preclinical autoimmune program CUE-401. The company will also discuss additional autoimmune pipeline developments and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
conferences
-
Rhea-AI Summary
Cue Biopharma, Inc. (Nasdaq: CUE) announces the presentation of CUE-101 at the 2024 Multi-disciplinary Head and Neck Cancers Symposium. The data highlights include an overall response rate of 47% in first-line patients and a median overall survival of 20.8 months in second-line patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
Rhea-AI Summary
Cue Biopharma, Inc. (Nasdaq: CUE) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, providing a corporate update on its lead clinical programs, CUE-101 and CUE-102, as well as its lead preclinical autoimmune program partnered with Ono Pharmaceutical. The presentation will also cover market opportunities, competitive positioning, and key forecasted value-driving 2024 milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
conferences

FAQ

What is Cue Biopharma's main focus?

Cue Biopharma is focused on developing injectable biologics to selectively engage and modulate disease-specific T cells for treating cancers and autoimmune disorders.

What are CUE-101 and CUE-102?

CUE-101 is being developed for HPV16+ head and neck squamous cell carcinoma, while CUE-102 targets Wilms' Tumor 1 (WT1)-expressing cancers such as colorectal, gastric, and pancreatic cancers.

Where is Cue Biopharma headquartered?

Cue Biopharma is headquartered in Boston, Massachusetts.

What is the Immuno-STAT™ platform?

The Immuno-STAT™ platform is a proprietary technology designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic immune modulation.

Who are Cue Biopharma’s strategic partners?

Cue Biopharma has partnered with Ono Pharmaceutical for its autoimmune and inflammatory disease program, CUE-401.

What recent financial achievements has Cue Biopharma made?

Cue Biopharma has reported increased collaboration revenue due to its agreement with Ono Pharmaceutical and maintains a strong cash position to fund operations into the first quarter of 2025.

What is the status of the CUE-101 clinical trials?

CUE-101 is in Phase 1 trials for treating HPV16+ head and neck squamous cell carcinoma, both as a monotherapy and in combination with pembrolizumab. Recent data shows prolonged overall survival and enhanced clinical activity.

What does the CUE-102 program aim to achieve?

CUE-102 aims to treat Wilms' Tumor 1 (WT1)-expressing cancers by selectively activating WT1-specific T cells. Early trial data shows expansion of these T cells and favorable tolerability.

What is CUE-401?

CUE-401 is a preclinical program focused on autoimmune and inflammatory diseases, aiming to redirect virus-specific T cells to deplete B cells in autoimmune conditions.

What is the company's financial outlook?

Cue Biopharma expects its current cash and cash equivalents to fund operations into the first quarter of 2025.

Cue Biopharma, Inc.

Nasdaq:CUE

CUE Rankings

CUE Stock Data

66.15M
45.38M
2.97%
32.9%
8.64%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
BOSTON